Print

Actelion Pharmaceuticals US, Inc. (ATLN.VX) Announces Commercial Availability of Epoprostenol for Injection for the Treatment of Pulmonary Arterial Hypertension  
4/22/2010 10:47:20 AM

SOUTH SAN FRANCISCO, Calif., April 22 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc. today announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and Class IV patients. Simultaneously, the company has launched the PROSPECT registry, a multicenter, observational, U.S.-based registry that will provide additional clinical experience on patients being treated with Epoprostenol for Injection.
//-->